Xilio Therapeutics (XLO) Net Cash Flow (QoQ) (2021 - 2026)
Xilio Therapeutics (XLO) Net Cash Flow (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,192.35 Bn | 67,192.06 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.52 Bn | 466.73 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.73 Bn | 114.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.88 Bn | 61.13 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.11 Bn | 63.11 Bn | - |
| 8 | Argenx Se | 55.88 Bn | 50.70 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Xilio Therapeutics | 144.35 Mn | -5.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.08% |
| Dec 31, 2025 | 289.95% |
| Sep 30, 2025 | -154.73% |
| Jun 30, 2025 | -3.86% |
| Mar 31, 2025 | 666.82% |
| Dec 31, 2024 | 56.44% |
| Sep 30, 2024 | -134.21% |
| Jun 30, 2024 | 518.89% |
| Mar 31, 2024 | 36.60% |
| Dec 31, 2023 | 3.49% |
| Sep 30, 2023 | 12.73% |
| Jun 30, 2023 | 34.03% |
| Mar 31, 2023 | -44.55% |
| Dec 31, 2022 | 7.46% |
| Sep 30, 2022 | -15.48% |
| Jun 30, 2022 | 16.81% |
| Mar 31, 2022 | -121.46% |
| Dec 31, 2021 | 578.70% |
| Sep 30, 2021 | 1.87% |
| Jun 30, 2021 | -117.15% |